- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01628081
The Effect of Alga Dunaliella Bardawil on Psoriasis
A Randomized, Double-Blind, , Placebo Controlled, 18 Week Study To Evaluate the Efficacy of Adjuvant 9-cis-β-Carotene Rich Powder of the Alga Dunaliella Bardawil in Subjects With Plaque Type Psoriasis.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Subjects will be screened for eligibility at the baseline visit for blood tests.
After screen phase of maximum two weeks the subjects will be randomized to one of two treatments groups (1:1): Dunaliella or placebo.
Each subject will have a final evaluation 4 weeks after the end of study drug treatment.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Tel-Hashomer, Israel, 52621
- Recruiting
- The Bert W. Strassburger Lipid Center,Sheba Medical Center
-
Principal Investigator:
- Shoshna Greenberger, MD
-
Tel-Hashomer, Israel, 52621
- Recruiting
- The Bert W. Strassburger Lipid Center
-
Sub-Investigator:
- Ofir Artzi, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects, ≥ 18 to ≤ 75 years of age, who have a diagnosis of plaque or guttate psoriasis;
- Psoriasis covering ≤ 20% of body surface area (BSA)
- Have at least 2 psoriatic plaques measuring 3 cm or more.
- For a female subject; either:
- subject is non-childbearing potential, defined as: menopause with amenorrhea > 2 years, hysterectomy, or bilateral oophorectomy or
- agrees to continue to use adequate contraception (i.e., hormonal [oral, depot, patch], IUD, barrier and spermicide) throughout the study and for at least one month following termination and have a negative urinary pregnancy test at screening and before the first dose of study drug;
- In the opinion of the Investigator, the subject will be compliant and have a high probability of completing the study and all required procedures.
Exclusion Criteria:
- The subject presents with the predominant type of psoriasis as erythrodermic, inverse, pustular or palmo-plantar or an unstable form of psoriasis;
- Received any investigational drug within 30 days of randomization.
- The subject has not used the following psoriasis treatment for the elaborated periods, prior to the date of screening visit:
Topical psoriasis treatment, excluding emollients 2-week period Any systemic psoriasis treatment including biologic treatments 4-week or 5-half life time periods (whichever is longer) Phototherapy or Climatotherapy 4-week period
- The subject has a known allergy or sensitivity to the study treatment(s) or to any of the percipient contained in the study drug formulation
- Any other acute or chronic medical condition that, in the opinion of the Investigator, increases the risk to the subject or the likelihood that the subject will be unable to complete the study;
- Subjects with any laboratory test at screening considered significantly abnormal.
The following will be considered significantly abnormal:
Alanine transaminase (ALT), aspartate transaminase (AST) > 3 upper limit normal. CPK > 3 upper limit normal. Triglycerides > 350mg/dl.
cytopenia (to include any of the following: WBC < 35000/μL; Hgb < 10 g/dL; platelets <120,000/μL; neutrophils absolute < 1500/μL lymphocytes absolute < 800/μL) or
- Known serologic positively for human immunodeficiency virus or hepatitis B or hepatitis C virus.
- History of substance abuse, including alcohol abuse, within the past year.
- History or current clinically significant major psychiatric disorder (e.g., major depressive disorder, psychosis, schizophrenia) according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV TR) [Exception; subjects with depression that has been adequately controlled for at least 6 months may enroll in the study];
- Female subject with a positive pregnancy test or nursing, or planning a pregnancy during the course of the study;
- Unwilling or unable to comply with study requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Alga Dunaliella bardawil
After screen phase of maximum two weeks the subjects will be randomized to one of two treatments groups (1:1): Dunaliella or placebo.
|
Dosage Regimen and Treatment Groups
|
PLACEBO_COMPARATOR: Placebo
Dosage Regimen and Treatment Groups
|
Dosage Regimen and Treatment Groups
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent change from baseline (predose day 1) to 18-week period Target Lesion Severity score (TLS) of lesions
Time Frame: Subjects will have study visits at screening- visit 1, randomization - visit 2, after 6 weeks treatment - visit 3, 12 weeks treatment -end of treatment - visit 4 and week 16 - follow up visit 5.
|
Target lesions will be evaluated for 3 components: erythema, induration, and scaling.
Each component will be given a score using the following scale: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked.
The Target Lesion Severity (TLS) score is calculated as a sum of the 3 components.
|
Subjects will have study visits at screening- visit 1, randomization - visit 2, after 6 weeks treatment - visit 3, 12 weeks treatment -end of treatment - visit 4 and week 16 - follow up visit 5.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Shoshana Greenberg, MD, Sheba Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHEBA-12-9174-SG-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis
-
ProgenaBiomeRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaUnited States
-
Clin4allRecruitingPsoriasis of Scalp | Psoriasis Nail | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrance
-
Innovaderm Research Inc.CompletedScalp Psoriasis | Pustular Palmo-plantar Psoriasis | Non-pustular Palmo-plantar Psoriasis | Elbow Psoriasis | Lower Leg PsoriasisCanada
-
Centre of Evidence of the French Society of DermatologyRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis PustularFrance
-
UCB Biopharma S.P.R.L.CompletedModerate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic PsoriasisJapan
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
-
TakedaRecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Janssen Pharmaceutical K.K.RecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Eli Lilly and CompanyCompletedGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingGeneralized Pustular Psoriasis (GPP)China
Clinical Trials on Dunaliella Bardawil
-
Sheba Medical CenterCompleted
-
Sheba Medical CenterCompleted
-
Sheba Medical CenterWithdrawn
-
Sheba Medical CenterActive, not recruitingRetinitis PigmentosaIsrael
-
Sheba Medical CenterNot yet recruiting
-
Sheba Medical CenterCompleted
-
Bnai Zion Medical CenterUnknownCrohn's DiseaseIsrael